Genmab licenses agiogenesis targets from Bionomics

16-Feb-2006

Genmab A/S and Bionomics Limited announced that Genmab has acquired exclusive worldwide rights to develop therapeutics based upon a series of angiogenesis targets identified by Bionomics. Under the agreement, Genmab has acquired exclusive worldwide rights to eight proteins identified and characterized by Bionomics using its proprietary Angene® angiogenesis platform with potential utility in cancer and other diseases.

Under the terms of the deal, Bionomics will receive an upfront fee and additional fees upon the first target achieving specified preclinical and clinical milestones. Bionomics will also receive milestone payments and royalties on product sales for each product that reaches the market.

Bionomics will retain rights to a large number of additional proprietary proteins it has discovered in its angiogenesis program, including, BNO69. Bionomics is continuing to develop BNO69 as a target for small molecule therapeutics for the treatment of breast cancer.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances